GSK Licenses Shigella Vaccine to Bharat Biotech

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the company’s effort to get the vaccine to patients where the pathogen poses a significant threat of causing death from diarrhea.

A closeup of a vial of the biotechnology company’s vaccines.

Shigella is responsible for the deaths of tens of thousands of children under five years in low and middle-income countries. GSK has developed altSonflex 1-2-3 to address the unmet need. Phase 1 and interim Phase 2 data of the candidate vaccine have already met the company’s immunogenicity success criteria.

Bharat Biotech will take charge of the continued development of altSonflex1-2-3, which encompasses Phase 3 clinical trials, regulatory progress, and large-scale production. GSK will support the initiative by helping design clinical trials, obtaining external financing, and aiding in access, delivery, and commercialization strategies.

GSK plc (NYSE:GSK) is a global pharmaceutical company focused on the discovery, development, and manufacture of medicines and vaccines. Its products are distributed worldwide through a broad network of wholesalers, pharmacies, hospitals, and healthcare providers.

While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.

Source link